ITGB3 and cancer: Since our findings are inconsistent with the traditional view that ITGβ3 is upregulated in cancers, and since the current clinical efficacy of ITGβ3-targeted drugs is uncertain, it is not recommended to try ITGβ3-targeted drugs in COAD.